Innoviva, Inc. (INVA) FY2025 10-K Annual Report
Innoviva, Inc. (INVA) 10-K annual report for fiscal year 2025, filed with SEC EDGAR on Feb 25, 2026. This page provides AI-powered analysis including business overview, management discussion & analysis (MD&A), risk factors, and key financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE) extracted from XBRL.
Innoviva, Inc. FY2025 10-K Analysis
Business Overview
- • Core business: diversified biopharmaceutical company with royalties portfolio plus critical care and infectious disease operating platform (Innoviva Specialty Therapeutics)
- • New products launched: XACDURO® (2023), ZEVTERA® (Q3 2025), and FDA approval of NUZOLVENCE® (Dec 2025) for infectious diseases
Management Discussion & Analysis
- • Revenue details and YoY change not disclosed in provided MD&A excerpt
- • Profitability or margin data not included in provided text
Risk Factors
- • FDA approval of NUZOLVENCE® in Dec 2025, with commercialization planned in H2 2026, regulatory risk around market launch and adoption timing
- • Pricing pressures in U.S. caused 2% decline in royalty revenue to $236.5M in 2025, signaling macroeconomic risk on revenue from GSK royalty portfolio
Innoviva, Inc. FY2025 Key Financial MetricsXBRL
Revenue
$411M
▲ +14.7% YoY
Net Income
$271M
▲ +1059.2% YoY
Gross Margin
74.8%
▼ -778bp YoY
Operating Margin
39.8%
▼ -671bp YoY
Net Margin
65.9%
▲ +5940bp YoY
ROE
23.1%
▲ +1974bp YoY
Total Assets
$1.6B
▲ +25.7% YoY
EPS (Diluted)
$3.30
▲ +816.7% YoY
Operating Cash Flow
$197M
▲ +4.4% YoY
Source: XBRL data from Innoviva, Inc. FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on Innoviva, Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.